Japanese CRO CMIC adopted Lokavant's machine learning Oversight platform to predict and manage trial risk.

CMIC, supporting over 80% of new drug development in Japan, relied on slow manual processes to find clinical trial risks and could not proactively predict data issues or budget overruns. It signed a multi-year deal for Lokavant's Oversight platform. The article gives no quantified outcomes.

Lokavant is a clinical trial intelligence company, spun out of Roivant, used by sponsors and CROs for risk monitoring and AI feasibility forecasting

This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.